ADALAT CC (nifedipine) by Charter Medical is clinical pharmacology nifedipine is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist) which inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. First approved in 1993.
Drug data last refreshed 22m ago · AI intelligence enriched 1w ago
ADALAT CC is an extended-release oral tablet formulation of nifedipine, a calcium channel blocker approved in 1993. It reduces arterial blood pressure by inhibiting calcium ion influx into vascular smooth muscle, causing peripheral arterial vasodilation and decreased peripheral vascular resistance. The extended-release formulation provides once-daily dosing with reduced plasma concentration fluctuations compared to immediate-release formulations.
Product approaching loss of exclusivity with moderate competitive pressure (30), indicating significant team restructuring and focus shift toward generic transitions or pipeline management.
CLINICAL PHARMACOLOGY Nifedipine is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist) which inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. The contractile processes of vascular smooth muscle and cardiac muscle are…
Worked on ADALAT CC at Charter Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan Cilexetil
Effectiveness and Tolerability of Long-Acting Nifedipine Gastrointestinal Therapeutic System in Chronic Kidney Disease With Uncontrolled Hypertension Patients, a Prospective, Multicenter, Observational Study
Comparison of Nifedipine Versus Indomethacin for Acute Preterm Labor
Nifedipine GITS and Amlodipine Besylate on Recovery of Blood Pressure Rhythm and Arterial Stiffness
Effect of Nifedipine GITS in Patients With Mild-to-moderate Primary Hypertension
Working on ADALAT CC offers stable, established-product experience in a mature cardiovascular therapeutic area with significant commercial and regulatory infrastructure. This role is best suited for professionals seeking deep expertise in hypertension management, generic transition strategy, and cost-containment initiatives rather than launch-phase or high-growth career acceleration.